 |
Business Wire - September 28, 2004
"Adherence to an effective antiretroviral regimen is the most important determinant of patient survival in HIV/AIDS," says Jeffrey Laurence, M.D., Editor of Medication Adherence in HIV/AIDS, Professor of Medicine at Weill Medical College of Cornell University, and Senior Scientific Consultant for programs at the American Foundation for AIDS Research.
"Medication adherence has been suboptimal ever since the introduction of highly active antiretroviral therapy (HAART)," says Dr. Laurence. "It is becoming clear that not all methods to promote adherence work in all HIV risk groups. They must take into account numerous psychosocial and behavioral issues, which are discussed in depth in this book."
"Successful therapy depends on achieving complete virus suppression," writes William G. Powderly, M.D., of the University College of Dublin, in the book's Preface. If antiviral therapy is inadequate and the virus is able to replicate, then drug resistance can develop and available medications become less effective.
"Apart from the implications for the health of an individual patient, medication adherence has broad implications for the AIDS epidemic. Inadequate adherence facilitates the development of drug resistant strains of virus, which can then be transmitted to others and fuel the epidemic," adds Dr. Laurence.
Medication Adherence in HIV/AIDS defines the scope of the problem, presents solutions, describes valuable measuring instruments and predictors, and includes sections on the challenges of medication adherence in special populations such as minorities, adolescents, pregnant women, and drug abusers. A complete table of contents and ordering information are available at www.liebertpub.com/medadh.
Mary Ann Liebert, Inc., is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including AIDS Patient Care and STDs and AIDS Research and Human Retroviruses. Its biotechnology trade magazine, Genetic Engineering News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 60 journals, books, and newsmagazines is available at www.liebertpub.com
CONTACT: Mary Ann Liebert, Inc., Larchmont
Vicki Cohn, 914-834-3100, ext. 617
vcohn@liebertpub.com
SOURCE: Mary Ann Liebert, Inc.
040928
BW040909
Copyright © 2004 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, Bridgestone/Firestone Charitable Trust, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .